GRP and non-small cell lung carcinoma: In conclusion, bevacizumab targeted therapy combined with chemotherapy and nursing intervention could improve the clinical outcome and lung function of patients with non-small-cell lung cancer and reduce serum CYFRA21-1 and ProGRP levels while improving the survival time of patients with good prognosis and high safety, which was worthy of clinical reference.